Table 3.
Unadjusted and Propensity‐Matched Association Between New MRA Use and Outcomes
| Outcome | Unadjusted | Propensity‐Matched | ||
|---|---|---|---|---|
| HR or OR (95% CI) | P Value | HR or OR (95% CI) | P Value | |
| AF progressiona | 1.36 (0.99–1.88) | 0.0598 | 1.18 (0.88–1.58) | 0.2731 |
| All‐cause death | 1.82 (1.21–2.72) | 0.0038 | 1.09 (0.67–1.79) | 0.7303 |
| Cardiovascular death | 1.87 (0.90–3.87) | 0.0941 | 0.97 (0.43–2.15) | 0.9319 |
| First stroke, non‐CNS embolism, or TIA | 0.19 (0.03–1.41) | 0.1055 | 0.17 (0.02–1.23) | 0.0792 |
| New‐onset HF | 2.61 (1.02–6.66) | 0.0443 | 1.73 (0.54–5.57) | 0.3587 |
| First cardiovascular hospitalization | 1.49 (1.16–1.92) | 0.0016 | 1.09 (0.85–1.39) | 0.5020 |
AF indicates atrial fibrillation; CI, confidence interval; CNS, central nervous system; HF, heart failure; HR, hazard ratio; MRA, mineralocorticoid antagonist; TIA, transient ischemic attack.
a
Odds ratio (OR) reported.